CN112292379A - 吡啶并吡啶酮衍生物的盐型及晶型 - Google Patents

吡啶并吡啶酮衍生物的盐型及晶型 Download PDF

Info

Publication number
CN112292379A
CN112292379A CN201980040138.5A CN201980040138A CN112292379A CN 112292379 A CN112292379 A CN 112292379A CN 201980040138 A CN201980040138 A CN 201980040138A CN 112292379 A CN112292379 A CN 112292379A
Authority
CN
China
Prior art keywords
compound
crystalline form
reaction
formula
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980040138.5A
Other languages
English (en)
Other versions
CN112292379B (zh
Inventor
徐招兵
蔡进峰
刘迎春
宋宝慧
施沈一
姚婷
胡利红
丁照中
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KEYSTONE
CStone Pharmaceuticals Shanghai Co Ltd
CStone Pharmaceuticals Suzhou Co Ltd
CStone Pharmaceuticals
Original Assignee
KEYSTONE
CStone Pharmaceuticals Shanghai Co Ltd
CStone Pharmaceuticals Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KEYSTONE, CStone Pharmaceuticals Shanghai Co Ltd, CStone Pharmaceuticals Suzhou Co Ltd filed Critical KEYSTONE
Publication of CN112292379A publication Critical patent/CN112292379A/zh
Application granted granted Critical
Publication of CN112292379B publication Critical patent/CN112292379B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种吡啶并吡啶酮衍生物的盐型、晶型及其制备方法，具体公开了式(I)化合物的盐酸盐及其盐酸盐的晶型，还包括所述晶型和盐型在制备治疗肺癌与其他癌症药物中的应用。
Figure DDA0002835084440000011

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201980040138.5A 2018-06-13 2019-06-13 吡啶并吡啶酮衍生物的盐型及晶型 Active CN112292379B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810609544 2018-06-13
CN2018106095446 2018-06-13
PCT/CN2019/091073 WO2019238088A1 (zh) 2018-06-13 2019-06-13 吡啶并吡啶酮衍生物的盐型及晶型

Publications (2)

Publication Number Publication Date
CN112292379A true CN112292379A (zh) 2021-01-29
CN112292379B CN112292379B (zh) 2022-03-04

Family

ID=68842805

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980040138.5A Active CN112292379B (zh) 2018-06-13 2019-06-13 吡啶并吡啶酮衍生物的盐型及晶型

Country Status (2)

Country Link
CN (1) CN112292379B (zh)
WO (1) WO2019238088A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014128588A1 (en) * 2013-02-21 2014-08-28 Pfizer Inc. Solid forms of a selective cdk4/6 inhibitor
WO2017054484A1 (zh) * 2015-09-30 2017-04-06 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
WO2017101763A1 (en) * 2015-12-13 2017-06-22 Hangzhou Innogate Pharma Co., Ltd. Heterocycles useful as anti-cancer agents
CN107955019A (zh) * 2016-10-17 2018-04-24 广东众生药业股份有限公司 一种egfr抑制剂的盐型、晶型及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10676474B2 (en) * 2016-12-16 2020-06-09 Cstone Pharmaceuticals 1,6-naphthyridine derivatives as CDK4/6 inhibitor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014128588A1 (en) * 2013-02-21 2014-08-28 Pfizer Inc. Solid forms of a selective cdk4/6 inhibitor
WO2017054484A1 (zh) * 2015-09-30 2017-04-06 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
WO2017101763A1 (en) * 2015-12-13 2017-06-22 Hangzhou Innogate Pharma Co., Ltd. Heterocycles useful as anti-cancer agents
CN107955019A (zh) * 2016-10-17 2018-04-24 广东众生药业股份有限公司 一种egfr抑制剂的盐型、晶型及其制备方法

Also Published As

Publication number Publication date
WO2019238088A1 (zh) 2019-12-19
CN112292379B (zh) 2022-03-04

Similar Documents

Publication Publication Date Title
CN110382495B (zh) Cdk4/6抑制剂
CN109689641B (zh) 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法
EP3218366B1 (en) Aurora a kinase inhibitor
CN103930408B (zh) 用于癌症治疗的吗啉基苯并三嗪
US9067920B2 (en) Compounds useful for inhibiting Chk1
CN114728957B (zh) 一种atr抑制剂的晶型及其应用
CN107362166B (zh) 四氢吡啶并[4,5-]噻吩并[2,3-]嘧啶-4(3)-酮类化合物在制药中的应用
WO2019057757A1 (en) 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
CN112292379B (zh) 吡啶并吡啶酮衍生物的盐型及晶型
CN115466266B (zh) mTOR蛋白降解靶向嵌合体及其制备方法和应用
JP2019513730A (ja) 癌を治療するためのＡＴＭ（毛細血管拡張性運動失調症変異）キナーゼモジュレータとしてのＮ，Ｎ−ジメチル−３−［［５−（３−メチル−２−オキソ−１−テトラヒドロピラン−４−イル−イミダゾ［４，５−ｃ］キノリン−８−イル）−２−ピリジル］オキシ］プロパン−１−アミンオキシド
CN115448874A (zh) 固体形式的周期蛋白依赖性激酶9抑制剂及其用途
CN113260613B (zh) 一种egfr抑制剂的盐、晶型及其制备方法
AU2019260240B2 (en) Crystal form of c-MET inhibitor and salt form thereof and preparation method therefor
CN116018343A (zh) 一种吡啶并嘧啶化合物的晶型
JP2022536574A (ja) 固体形態のｂｒｄ４阻害剤化合物およびその調製方法およびその使用
CN111333655A (zh) 一种三唑并嘧啶类化合物及其制备方法和应用
CN114957249B (zh) 一种不可逆共价结合cdk抑制剂及其制备方法和应用
CN117355528B (zh) 吡咯并三嗪类化合物的盐型、其晶型及其制备方法
CN111423435B (zh) (1H-咪唑并[4,5-b]吡啶-6-基)吡啶衍生物及其应用
EP4130004A1 (en) Salt and crystalline forms of fgfr4 inhibitor and uses thereof
EP3964510A1 (en) Crystal form of wee1 inhibitor compound and use thereof
CN106661064A (zh) 一种抗癌化合物的新晶型及其制备方法和用途
KR20220128419A (ko) 아자인돌 유도체의 결정형 및 그 응용
CN116685588A (zh) 吡啶并吡咯类化合物的晶型、制备方法及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant